NEW YORK (GenomeWeb) – MiRxes, a Singapore-based life sciences and molecular diagnostics company, has expanded its global activities in recent weeks obtaining a CE-IVD mark for a quantitative PCR-based gastric cancer test, while establishing a US subsidiary and naming distributors to sell its products across Europe, the Middle East, and Asia.
Ray Ong, the company’s head of business development, said that MiRxes has enjoyed increasing support from cancer researchers in Singapore and has taken part in projects with local pharmaceutical companies, the success of which has encouraged the firm to now expand abroad.
“Over the last two years … we have secured a good share of the local microRNA technology market, and we have to expand to the global arena in order to continue this growth,” Ong said.
MiRxes commenced operations in 2014 when it launched its mSMRT-qPCR platform, which enables users to identify circulating miRNA biomarkers using existing qPCR workflows. The approach has been seen by some as an ideal method for detecting the molecules, given their limited length of 18 to 22 base pairs. The company is privately held, and employs 30 staffers at its Singapore headquarters, Ong said, though it plans to increase headcount in the coming